Clinical Trial Update: Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS) [Phase 4]

View source ↗

Summary

Phase 4 trial BADCATS evaluating beta-1 adrenergic inhibition to reduce cardiac injury and inflammation after non-traumatic subarachnoid hemorrhage is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-traumatic Subarachnoid Hemorrhage

Drugs mentioned

• Beta-1 Adrenergic Inhibition (BADCATS trial)

Snippet

Sponsor: Madeleine Puissant | Conditions: Non-Traumatic Subarachnoid Hemorrhage | Phase 4 | Status: RECRUITING